| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
5-HT1A Receptor (Ki = 0.12 nM); 5-HT2A Receptor (Ki = 0.47 nM); D2 Receptor (Ki = 0.3 nM)
The primary targets of Brexpiprazole S-oxide are serotonin 5-HT1A receptors and dopamine D2 receptors, where it acts as a partial agonist. It also has antagonist activity at 5-HT2A receptors and α1B-adrenergic receptors. As a partial agonist at D2 receptors, it modulates dopaminergic signaling with reduced risk of extrapyramidal side effects compared to full antagonists. 5-HT1A partial agonism contributes to its antidepressant and anxiolytic effects. The metabolite has a similar receptor binding profile to the parent compound Brexpiprazole. |
|---|---|
| ln Vitro |
As a new atypical antipsychotic, brexpiprazole is primarily metabolized by cytochrome P450 3A4 (CYP3A4). However, genetic polymorphisms in CYP3A4 cause wide variability in individuals' responses to brexpiprazole, leading to unpredictable adverse side effects or even therapeutic failure. The present study was designed to systematically study the effects of 26 recombinant CYP3A4 variants on the metabolism of brexpiprazole and investigate their enzymatic activity. Wild-type CYP3A4 and the 26 variants were incubated with the substrate brexpiprazole for 30 min at 37 °C. The metabolite DM-3411 was detected using ultraperformance liquid chromatography-tandem mass spectrometry. The activity of the wild-type CYP3A4 and 26 of its variants was analyzed. Then, the mechanism underlying the changes in enzyme function was observed using molecular dynamics simulations and molecular docking. Compared with CYP3A4.1, the enzymatic activities of CYP3A4.19, -.24, and -.28 were not significantly different (from 91.82% to 96.25%), but CYP3A4.14 and CYP3A4.15 exhibited higher enzyme activity (from 117.9 to 127.5%). The remaining 21 isoforms, including CYP3A4.2, -.3, -.4, -.5, -.7, -.8, -.9, -.10, -.11, -.12, -.13, -.16, -.17, -.18, -.20, -.23, -.29, -.31, -.32, -.33 and -.34, displayed lower enzymatic activities (from 2.90% to 75.72%). The results obtained from computer modeling indicated that weak binding affinity impaired the function of CYP3A4.32. Mutations that occur around the active site might lead to a loss of enzymatic activity, while the variants located far away from the active site perhaps had little effect on function of CYP3A4. These comprehensive data provide a reference and prediction for treatment strategies and risk assessments of brexpiprazole [1].
In vitro, Brexpiprazole S-oxide binds to human 5-HT1A receptors with a Ki of 0.12 nM and to dopamine D2 receptors with a Ki of 0.3 nM. It acts as a partial agonist at both receptors, with intrinsic activity of approximately 50-60% relative to full agonists. It antagonizes 5-HT2A receptor-mediated signaling with a Ki of 0.5 nM. The metabolite inhibits dopamine-stimulated GTPγS binding and serotonin-stimulated inositol phosphate production in a concentration-dependent manner. |
| ln Vivo |
In vivo, Brexpiprazole S-oxide is formed after oral administration of Brexpiprazole in humans and animals. It circulates in plasma and contributes to the therapeutic effects of Brexpiprazole. The metabolite is eliminated primarily by renal excretion. Brexpiprazole itself is effective in animal models of schizophrenia and depression, including apomorphine-induced climbing and forced swim test. The metabolite is used as a reference standard for therapeutic drug monitoring.
|
| Enzyme Assay |
For non-cell receptor binding assays, Brexpiprazole S-oxide is evaluated using radioligand binding assays with [3H]-8-OH-DPAT (5-HT1A) and [3H]-spiperone (D2) and membranes from cells expressing recombinant receptors. Competitive displacement curves are generated to determine Ki values. GTPγS binding assays are performed to assess partial agonist activity. Selectivity against other receptors (5-HT2A, D3, α1) is confirmed.
|
| Cell Assay |
In vitro cell experiments with Brexpiprazole S-oxide involve culturing cells expressing 5-HT1A or D2 receptors (e.g., CHO-5-HT1A, HEK293-D2). Cells are treated with Brexpiprazole S-oxide at concentrations ranging from 0.01 to 100 nM for 15-60 minutes. cAMP accumulation is measured by ELISA. Inositol phosphate production is measured by scintillation proximity assay. Receptor internalization is assessed by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments with Brexpiprazole S-oxide are primarily pharmacokinetic studies. The metabolite is administered intravenously or orally to rats or mice at doses ranging from 0.1 to 10 mg/kg, and plasma and brain tissue samples are collected at various time points for LC-MS/MS analysis. For behavioral studies, Brexpiprazole (unlabeled) is administered in animal models of schizophrenia (apomorphine-induced climbing, MK-801-induced hyperactivity) and depression (forced swim test).
|
| References |
|
| Additional Infomation |
Brexpiprazole is a novel atypical antipsychotic drug currently undergoing clinical trials for the treatment of mental illnesses such as schizophrenia and major depressive disorder. It is known to exert its effects through partial agonism of serotonin (5-HT) 1A receptors and dopamine D2 receptors, as well as antagonism of 5-HT2A receptors. Increasing evidence suggests that antipsychotic drugs exert their effects by promoting neurite growth. In this study, we investigated whether Brexpiprazole affects neurite growth in cell culture. We found that Brexpiprazole significantly enhanced nerve growth factor (NGF)-induced neurite growth in PC12 cells in a concentration-dependent manner. The selective 5-HT1A receptor antagonist WAY-100,635 blocked the effect of Brexpiprazole on neurite growth, while the selective dopamine D2 receptor antagonist raclopride did not. Furthermore, the selective 5-HT2A receptor antagonist M100907 (rather than the 5-HT2A receptor agonist DOI) significantly enhanced NGF-induced neurite growth. In addition, xestospongin C and 2-aminoethoxydiphenylboronic acid ester (2-APB), specific inhibitors of the inositol 1,4,5-triphosphate (IP3) receptor, significantly blocked the effects of brexpiprazole. These results suggest that brexpiprazole-induced neurite growth is mediated by 5-HT1A and 5-HT2A receptors, followed by Ca(2+) signaling via the IP3 receptor. [2]
|
| Molecular Formula |
C₂₅H₂₇N₃O₃S
|
|---|---|
| Molecular Weight |
449.57
|
| Exact Mass |
449.177
|
| CAS # |
1191900-51-2
|
| Related CAS # |
Brexpiprazole S-oxide-d8;2748605-29-8
|
| PubChem CID |
44256485
|
| Appearance |
Typically exists as Off-white to light yellow solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.693
|
| LogP |
3.1
|
| tPSA |
81.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
749
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1(C=CC2=C1C=CC=C2N1CCN(CCCCOC2=CC=C3C=CC(NC3=C2)=O)CC1)=O
|
| InChi Key |
VJYXYAVCCLPIPM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H27N3O3S/c29-25-9-7-19-6-8-20(18-22(19)26-25)31-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-32(24)30/h3-10,17-18H,1-2,11-16H2,(H,26,29)
|
| Chemical Name |
7-[4-[4-(1-oxo-1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
|
| Synonyms |
DM-3411; DM3411; Brexpiprazole S-oxide; 1191900-51-2; DM-3411; 2(1H)-Quinolinone, 7-(4-(4-(1-oxidobenzo(b)thien-4-yl)-1-piperazinyl)butoxy)-; BrexpiprazoleS-Oxide; N22UPQ09R0; UNII-N22UPQ09R0; 7-[4-[4-(1-oxo-1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one; DM 3411
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~55.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2243 mL | 11.1217 mL | 22.2435 mL | |
| 5 mM | 0.4449 mL | 2.2243 mL | 4.4487 mL | |
| 10 mM | 0.2224 mL | 1.1122 mL | 2.2243 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.